Background: Differentiation of urothelial hyperplasia, dysplasia and carcinoma in situ (CIS) may pose diagnostic difficulties. We aim to evaluate the role of CK20, p53 and p63 in differentiation of such lesions. Methods: we evaluate these markers in 213 cases of bladder lesions (14 hyperplasia, 7 dysplasia, 5 CIS, 25 noninvasive and 162 invasive urothelial carcinoma) in a retrospective study on sections from formalin-fixed, paraffin-embedded blocks. Cytoplasmic staining considered for CK20 and nuclear staining for p53 and p63. Results: CK20 was expressed in 14 out of 14 hyperplasia (4 strong, 7 moderate, 3 weak), in 7 out of 7 dysplasia (4 strong , 3 
Introduction
Urothelial carcinoma is the 7th most common cancer worldwide [1] . More than 50% of patients with non-invasive urothelial tumors have recurrences (or new occurrences), and 10% to 15% of these will progress to invasive cancer [2] . The most important predictive parameter for the biological behavior of urothelial carcinoma, except depth of invasion, is the histological grade of tumor [3] , although tumor grade and stage have been shown to have a strong correlation with tumor recurrence and progression to invasive bladder cancer [4] . A large number of markers have been extensively investigated as potential predictors of bladder tumor recurrence, progression, or response to therapy [2] . CK20 belongs to the epithelial subgroup of cytoskeleton-associated intermediate filaments. It has been suggested that CK20 may be an important tool for detecting and identifying these types of cancer (urothelial carcinoma) and may be used as a potential predictors of bladder tumor recurrence, progression, or response to therapy [5] . Mutated p53 gene is a common genetic abnormality in urothelial carcinoma of the bladder. Some studies have depicted that over expression of p53 occurs in higher stages and grades of urothelial carcinoma and over expression of the p53 gene product has been reported as a marker of progression in urothelial carcinoma [6] . p63, a member of the p53 gene family, encodes multiple proteins that may either transactivate p53 responsive genes or act as a dominant-negative factor toward p53. p63 is regulated in bladder carcinogenesis and p63 expression is lost in most invasive cancers whereas non invasive tumors maintain p63 expression [7] . CK20, p53 and p63 immunohistochemistry is suggested to be helpful to distinguish dysplastic changes and carcinoma in situ from reactive atypia [8] [9] .
Material and Methods
This work included 213 cases of different bladder lesions collected from Al-Azhar Faculty of Medicine Hospital labs during the period from January 2005 to January 2010; 43 radical cystectomies and 170 cystoscopic biopsies, 8 cases of normal urothelium included as a control. Four micron thick sections were cut from paraffin blocks of all cases and stained with haematoxylin and eosin (H & E). All cases were re-evaluated; graded and staged according to WHO classification 2004 of bladder tumors and TNM staging 2009 respectively. For immunohistochemistry, sections were taken on poly-L-lysine coated slides. The primary antibodies were as follows: CK20 (Monoclonal mouse anti human cytokeratin 20, Dako cooperation Denmark; colonic carcinoma as positive control & tumor stroma as negative control), p53 (Monoclonal mouse anti human p53, Lab Vision Cooperation Fremount USA; Breast cancer as positive control & normal liver tissue as negative control), p63 (Monoclonal mouse anti human p63, Biocare Medical Cooperation Concord USA; normal prostate as positive control & muscle tissue as negative control). Cytoplasmic staining was considered for CK20 and nuclear staining for p53 and p63. According to Yildiz's et al., (2009) [10] , CK20 cytoplasmic staining was evaluated: (0; no staining), (1+; patchy or/and weak), (2+; <50% cells, moderate), (3+; >50% cells, strong). p53 was evaluated according to number of positive cells (0; no staining), (1+; <15% cells, weak), (2+; 15% -50% cells, moderate), (3+; >50% cells, strong). According to Kaufmann's et al. (2001) [11] , p63 was evaluated according to the percentage of positive cells, (1+; 1% -10%), (2+; 11% -50%), and (3+; more than 50%).
Statistical Analysis
Statistical presentation and analysis of the present study was conducted, using the mean, standard error, student t-test and Chi-square by SPSS V17.Statistical significance was established as P < 0.05 [12] [13].
Results
This study consisted of 213 cases of bladder lesions and 8 cases of normal urothelium as a control. The age of the patients ranged from 29 to 84 years (mean: 59.4) with 204 males and 9 females.
Histopathological findings:
Urothelial hyperplasia (14 cases): of flat and papillary types, and associating different types of cystitis (6 bilharzial, 5 polypoid, 1 interstitial, 1 lymphoid and 1 hemorrhagic) (see Figure 1) .
Urothelial dysplasia (7 cases): with variable loss of polarity, irregular nuclear borders, inconspicuous nucleoli and rare mitoses, moderate in 5 cases and severe in 2 cases.
Urothelial CIS (5 cases): associating invasive carcinoma, showing high grade nuclear anaplasia, large pleomorphic nuclei, frequent mitoses, and involving the entire epithelial thickness (see Figure 2) .
Urothelial Figure 3 ). Immunohistochemical findings: CK20 Normal urothelium (8 cases): CK20 was expressed in all cases and localized to the superficial umbrella cell layer (strong in 1, moderate in 5 and weak in 2).
Urothelial Hyperplasia (14 cases): CK20 was expressed in all cases and limited to the superficial umbrella cell layer (strong in 4, moderate in 7 and weak in 3).
Urothelial Dysplasia (7 cases): CK20 was expressed in all cases, in upper 2/3 of urothelium in 6 cases (strong in 4 and moderate in 2), and moderate throughout the uroithelium in 1case, (see Figure 4 ). Urothelial CIS (5 cases): CK20 was strongly expressed throughout the urothelium in all cases.
Non-invasive papillary carcinoma (25 cases): CK20 was expressed in 19 cases (76%), strong in 11 (44%), moderate in 7 (28%) and weak in 1 (4%), (see Table 2 & Figure 5 ).
Invasive urothelial carcinoma (162 cases): CK20 was expressed in 136 cases (84%), strong in 46 (28.4%), moderate in 71 (43.9%) and weak in 19 (11.7%), (see Table 3 , Table 4 and Figure 6 ). p53 Normal urothelium (8 cases): p53 was expressed in 3 cases (37.5%; seen in basal and intermediate layers) while the other 5 cases showed no reactivity.
Urothelial hyperplasia (14 cases): p53 was expressed in 7 (50%; seen in basal and intermediate layers) while the other 7 cases showed no reactivity.
Urothelial Dysplasia (7 cases): p53 was expressed throughout the urothelium in all cases (strong in 5 and moderate in 2).
Urothelial CIS (5 cases): p53 was expressed throughout the urothelium in all cases, (see Figure 7) . Non-invasive papillary carcinoma (25 cases): p53 was expressed in 20 cases (80%), strong in 8 (32%), moderate in 9 (36%) and weak in 3 (12%), (see Table 5 & Figure 8 ).
Invasive urothelial carcinoma (162 cases): p53 was expressed in 135 cases (83.33%), strong in 34 (20.99%), moderate in 73 (45.06%) and weak in 28 (17.28%), (see Table 6 & Table 7 ). p63 Normal urothelium (8 cases): p63 was strongly expressed in basal and intermediate layers of all cases while the superficial umbrella cells showed no reactivity.
Urothelial Hyperplasia (14 cases): p63 was strongly expressed in basal and intermediate layers of all cases while the superficial umbrella cells showed no reactivity.
Urothelial Dysplasia (7 cases): p63 was expressed in all cases; strong in basal layers with gradual decrease towards the epithelial surface. Urothelial CIS (5 cases): p63 was strongly expressed throughout of the urothelium in 4 cases, and in basal layers with gradual decrease towards the epithelial surface in 1case.
Non-invasive papillary carcinoma (25 cases): p63 was expressed in all cases and ranged from moderate to strong, see (Table 8) .
Invasive urothelial carcinoma (162 cases): p63 was expressed in 134 cases (82.71%), strong in 28 (17.28 %), moderate in 63 (38.89%) and weak in 43 (26.54 %), see ( Table 9 & Table 10 ) and (Figure 9 ). 
Discussion
The aim of this work is to evaluate the role of CK20, p53 and p63 in differentiation between urothelial hyperplasia, dysplasia, and grade and stage of the urothelial carcinoma. In the current study, CK20 was expressed in all cases of normal urothelium and the expression was limited to the superficial umbrella cell layer and the reaction was moderate in most of cases, similar findings were reported by Southgate et al., (1999) [14] who noted that normal urothelium showed CK20 cytoplasmic immunoreactivity in the superficial umbrella cell layer and this was named the normal CK20 expression pattern. Castillo-Martin et al., (2010) [15] studied molecular pathways of urothelial development and bladder tumorigenesis and found that umbrella cells are characterized by expression of CK18 and CK20.
In this work, scattered CK20 immunoreactivity was demonstrated in all cases of dysplasia and the reaction was documented in the upper two thirds of the urothelial thickness in 85.7% of cases, it involved the whole thickness of the urothelium in 14.3%. these findings are parallel to those of Harnden et al., (1996) [16] who found that the expression of CK20 was restricted to superficial "umbrella" cells, even in the presence of severe inflammation while in the vast majority of cases of dysplasia, it was seen at least focally with positive expression in all layers of the urothelium.
In this work, all cases of CIS showed strong CK20 positivity in the majority of malignant cells and the positivity was through the full thickness of the urothelium. Similar findings were reported by Mallofré et al., 2003 [8] , (McKenney et al., 2001, Yin et al., 2006 & Nese et al., 2009) [17] - [19] who found intense CK20 positivity in the vast majority of cases of urothelial CIS in the majority of malignant cells through the full thickness of the urothelium.
In the current study, CK20 was expressed in 82.89% of the cases of urothelial carcinoma and the reaction was strong in 30.48%, moderate in 41.71% and weak in 10.7% of cases. Similar findings were reported by Moll et al., 1992 , Miettinen et al., 1995 and Wang et al., 1995 [20] - [22] who found the expression of CK20 in different human cancers and found that the majority of cases of urothelial carcinoma showed positive CK20 expression.
In this work, p53 was not expressed in non-neoplastic urothelium (including normal and hyperplastic urothelium) apart from occasional weak positivity in the basal and intermediate layers in some cases, these findings are parallel to those of Mallofré et al., 2003 [8] [23] who found that p53 immunoreactivity in normal urothelium ranged from negative to weak and patchy and in reactive urothelium, p53 expression was predominantly negative with occasional weak positivity in the basal and intermediate cells. These results support the view that the absence of p53 in urothelium points to its non neoplastic nature. However, Soukup et al., (2007) [24] found p53 positivity in some cases of non-tumor mucosa of urinary bladder in patients with superficial bladder cancer. These cases with p53 positivity in non-tumor mucosa showed higher recurrence rate than that with normal p53 negative non-tumor mucosa.
In this study, p53 positivity of moderate to strong intensity was documented in all the studied cases of dysplasia and the expression was scattered throughout the urothelium. Similar finding was reported by Yildiz et al., (2009) [10] who found that most of the cases of dysplasia had p53 positivity in scattered cells through the urothelium.
Many [19] demonstrated strong p53 positivity in the majority of cases of urothelial CIS in most of malignant cells throughout the urothelium, an expression similar to that found in the current study. Contrary to these findings are those of Nakopoulou et al., (1998) [25] who did not demonstrate p53 expression in the dysplastic urothelia examined.
In the current study, p53 was expressed in 82.89% of the cases of urothelial carcinoma and the reaction was strong in 22.46%, moderate in 43.85% and weak in 16.58% of cases. Similar findings were reported by (Thomas et al., 1994 , Burkhard et al., 1997 , Grossman et al., 1998 , Uchida et al., 2002 , Babjuk et al., 2003 & Venyo et al., 2010 [26] - [31] who found p53 expression in the majority of cases of urothelial carcinoma.
In the current study, in all cases of dysplasia and 1case of CIS, p63 expression showed a maximum intense reaction in the nuclei of basal epithelial cells, which was gradually diminished towards the epithelial surface. Most (80%) of the cases of CIS showed strong positivity for p63 in all layers of the urothelium.
Many [35] demonstrated that non-neoplastic urothelium (including normal and reactive hyperplastic urothelium) showed strong positive nuclear immunoreactivity to p63 in entire basal and parabasal cells but immunoreactivity was undetectable in umbrella cells, an expression similar to that found in all studied cases of the non-neoplastic urothelium in the current study.
In the current study, p63 was expressed in 85.02% of the cases of urothelial carcinoma and the reaction was strong in 27.81%, moderate in 34.22% and weak in 22.99% of cases. This agrees with the results of Kaufmann et al., (2001) [11] who found that the majority of cases (more than 70%) of urothelial carcinoma were p63 positive. This agrees also with the results of Di Como et al., (2002) [7] who studied the expression of p63 in some different human normal and tumor tissues and showed that p63 is expressed in most of the cases of urothelial carcinoma.
In the current study, p63 was expressed in all cases of non-invasive papillary urothelial carcinoma and the reaction ranged from moderate to strong in most of the cells. Similar findings were reported by Urist et al., (2002) [36] who found that low-grade papillary superficial bladder tumors expressed p63 in 93% of tumor cells. However in the high-grade superficial tumors, there was a significant reduction in p63 positivity to 68%.
In the current study, p63 was expressed in 83.33% of the cases of invasive urothelial carcinoma and the reac- 
Conclusion
We conclude that there is a role of CK20, p53 and p63 in differentiating non-neoplastic lesions, dysplastic lesions and urothelial carcinoma, and these markers can be used as potential predictors of biologic behavior of urothelial carcinoma. We recommended performing many prospective studies with clinical correlation between these markers and the progression of urothelial tumors with large series of patients.
